Evaluation of waning of IgG antibody responses after rVSVΔG-ZEBOV-GP and Ad26.ZEBOV, MVA-BN-Filo Ebola virus disease vaccines: a modelling study from the PREVAC randomized trial

rVSVΔG-ZEBOV-GP and Ad26.ZEBOV, MVA-BN-Filo are WHO-prequalified vaccination regimens against Ebola virus disease (EVD). Challenges associated with measuring long-term clinical protection warrant the evaluation of immune response kinetics after vaccination. Data from a large phase 2 randomized doubl...

Полное описание

Библиографические подробности

Главные авторы:	Simon Valayer, Marie Alexandre, Mélanie Prague, Abdoul Habib Beavogui, Seydou Doumbia, Mark Kieh, Brian Greenwood, Bailah Leigh, Marie Poupelin, Christine Schwimmer, Samba O. Sow, Irina Maljkovic Berry, Jens H. Kuhn, Daniela Fusco, Natasha Dubois Cauwelaert, Deborah Watson-Jones, Rodolphe Thiébaut, Yves Lévy, Yazdan Yazdanpanah, Laura Richert, Edouard Lhomme
Формат:	Artigo
Язык:	Inglês
Опубликовано:	Taylor & Francis Group 2025-12-01
Серии:	Emerging Microbes and Infections
Предметы:	Ebola virus disease vaccine immunogenicity antibody Western Africa modelling
Online-ссылка:	https://www.tandfonline.com/doi/10.1080/22221751.2024.2432353
Метки:	Добавить метку Нет меток, Требуется 1-ая метка записи!